Log In Request a Trial

Health Care Antitrust Weekly: TCF Launches Monthly Litigation and Investigations Tracker; Judge Rules in Teva Patent Case; Corcept at Risk of Losing Market Share, Per 2025 Formulary Design Changes

Published on Jan 15, 2025

The Federal Trade Commission publishes second report on PBMs, focusing on how the Big Three PBMs markup specialty generic drug prices. The PBMs enjoyed excess revenues of $7.3 billion, the FTC wrote in its report, comparing revenues to the National Average Drug Acquisition Cost (NADAC), an industry-respected benchmark that estimates what a drug costs to […]

RELATED ARTICLES | Editor’s picks

Merger Monthly: Scramble Over AI Companies Calls to Mind Past Tech Battles—And Enforcers’ Response to Them

For those not around for the decades-long string of events that led to Big Tech becoming the target of antitrust enforcers, you’re in luck. Companies’ current fights for dominance in artificial...

Jan 07, 2025 Read Now >

Nippon Steel/U.S. Steel: Legal Challenge to Biden Ban Faces Tough Odds

Nippon Steel faces a tough task in overturning President Joe Biden’s decision to block its proposed $14.9 billion acquisition of U.S. Steel, according to a Capitol Forum...

Jan 07, 2025 Read Now >

IBM/HashiCorp: Companies’ Optimism Increases as Early 2025 FTC Decision Approaches

The merging parties’ optimism of closing IBM’s attempted $6.4 billion takeover of HashiCorp is growing as the FTC approaches a decision early next year, sources familiar with the matter...

Dec 18, 2024 Read Now >

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

Request a Trial

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.